

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

LONDON and PHILADELPHIA - March 10, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami.

A live webcast of the presentation will be available in the investors section of the Company's website at <https://avacta.com/investors>. The webcast will be archived for at least 30 days following the presentation.

-Ends-

For further information from Avacta, please contact:

Avacta Group plc avacta.com
Michael Vinegrad, Group Communications
Director

Peel Hunt (Nomad and Broker) www.peelhunt.com
James Steel / Chris Golden / Patrick Birkholm

Panmure Liberum (Joint Broker) www.panmureliberum.com
Emma Earl / Will Goode / Mark Rogers

ICR Healthcare avacta@icrhealthcare.com
Mary-Jane Elliott / Jessica Hodgson / Max
Bennett

Investor Contact renee@thrustsc.com
Renee Leck
THRUST Strategic Communications

Media Contact Carly@carlyscadutoconsulting.com
Carly Scaduto
Carly Scaduto Consulting

About Avacta - avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBLGDXUSGDGUR